Bavarian Nordic stocks surge on mpox vaccine deal

Bavarian Nordic’s stock rose by 10.2% after receiving an order for 440,000 mpox vaccines from an undisclosed European country and increasing their revenue forecast for the year. The company now expects to achieve the higher end of its previously estimated revenue range, between 5 and 5.3 billion Danish kroner. According to Søren Løntoft Hansen, a senior analyst at Sydbank, the adjustment significantly contributed to the positive investor reaction. The only manufacturer of an approved mpox vaccine, Bavarian Nordic is expected to deliver up to ten million doses by 2025, with up to two million available this year. The demand for mpox vaccines has risen after WHO declared it a global health emergency. Bavarian Nordic’s half-year financial report shows a turnover of nearly 2.3 billion kroner, with expectations of three billion kroner in revenue for the second half of the year, driven by new mpox vaccine orders.